SciELO - Scientific Electronic Library Online

 
vol.39 suppl.1Alternativas farmacológicas para el tratamiento de la dependencia a la heroína: un nuevo reto en ColombiaLa hipnosis como intervención para la cesación del consumo de tabaco índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Colombiana de Psiquiatría

versión impresa ISSN 0034-7450

Resumen

MONTOYA, Iván D.. Research Advances in the Immunotherapies of Addictions. rev.colomb.psiquiatr. [online]. 2010, vol.39, suppl.1, pp.213s-223s. ISSN 0034-7450.

Introduction: Immunological therapies, either with vaccines (active immunization) or with antibodies (passive immunization), are being actively investigated in the management of complications of drug abuse. Objetive: To review the current state of research development of immunotherapies against nicotine, cocaine, heroin, methamphetamine and phencyclidine (PCP) with an emphasis on the clinical aspects. Method: Review the literature about the topic. Results: So far, immunotherapies evaluated in humans appear to be safe from a medical standpoint and effective. This mechanism prevents the activation of brain reinforcement mechanisms associated with the addictive effects of drugs and, eventually, the extinction of the drug addiction. Conclusion: In theory, vaccines could also be useful in preventing the development of addiction as well as to prevent the relapse of drug use. Currently, vaccines are being investigated against cocaine, heroin, methamphetamine and nicotine. Likewise, monoclonal antibodies are being investigated against cocaine, methamphetamine, nicotine and phencyclidine (PCP).

Palabras clave : Immunotherapy; vaccines; drug addiction; treatment.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons